The Future of Depression Care? An At-Home Ketamine Pill Nears Reality

SAN FRANCISCO, CA – August 12, 2026 – For millions grappling with treatment-resistant depression (TRD), the path to relief is often arduous, marked by a series of ineffective medications and burdensome clinical visits. Today, a new strategy emerged that could fundamentally reshape this landscape. Tasman Therapeutics announced a pivotal partnership with health technology leader Osmind, a collaboration designed to propel its investigational oral ketamine tablet, R-107, through late-stage trials and into patients' homes.

This isn't just another drug announcement; it's a glimpse into a future where the management of severe depression could become more accessible, convenient, and personalized. The partnership leverages Tasman's innovative drug development with Osmind's powerful real-world data platform, creating a blueprint for how the next generation of psychiatric treatments are developed, approved, and safely delivered at scale.

A New Paradigm for Patient Care

The central innovation is R-107 itself: an extended-release oral ketamine tablet designed for at-home use. This stands in stark contrast to current ketamine-based options for TRD. Johnson & Johnson's Spravato (esketamine), a nasal spray, has proven to be a commercial blockbuster but requires patients to visit a certified clinic for administration and remain for at least 90 minutes of post-dose observation under a strict FDA safety program. Similarly, off-label intravenous ketamine infusions necessitate lengthy clinic appointments.

Tasman's approach circumvents these barriers. The extended-release formulation of R-107 is engineered to provide therapeutic benefit while minimizing the intense dissociative side effects and blood pressure spikes associated with other forms of ketamine. This differentiated safety profile is the key to enabling safe self-administration. Evidence from Tasman's BEDROC Phase 2 study, published in the prestigious journal Nature Medicine, showed that R-107 produced a rapid and durable improvement in depression symptoms with a tolerability profile that supported at-home use. In that study, the median score on a scale measuring dissociation was zero, a remarkable result that underpins the company's vision for a take-home therapy.

"As we advance R-107 through Phase 3 and toward what we believe can be the first and only oral, at-home monotherapy for treatment-resistant depression, having a strategic partner with Osmind's data, technology footprint, clinical network, and operational and artificial intelligence expertise gives us a meaningful advantage," said Dan Browne, CEO of Tasman Therapeutics, in a statement.

The Strategic Advantage of Real-World Evidence

This is where the partnership becomes truly forward-thinking. Osmind is not merely a service provider; it is the engine that will help de-risk and accelerate R-107's journey. The company operates the largest network of interventional psychiatry practices in the U.S. and has amassed the world's most extensive real-world dataset on patients receiving novel, rapid-acting psychiatric drugs.

This trove of anonymized data, collected from over 1,000 clinics via its specialized electronic health record (EHR) platform, provides an unparalleled view of how these treatments work in the real world, outside the pristine conditions of a clinical trial. For Tasman's pivotal Phase 3 ROCKET program, this translates into a powerful strategic asset. Osmind's data will help optimize the trial's design, better characterize the drug's safety profile against existing treatments, and support a more robust regulatory submission to the FDA.

The collaboration will also streamline clinical trial site identification and awareness, tapping into Osmind's established network of clinics already treating the exact patient population R-107 aims to serve. This synergy between a drug developer and a data technology firm represents a modern approach to clinical research, using real-world evidence to build a stronger, more efficient path to approval.

Building a Bridge to Safe, Scalable Access

Looking beyond the anticipated 2027 data readout for the ROCKET program, the partnership lays the groundwork for a highly differentiated commercial launch. Bringing a controlled substance like ketamine into an at-home setting requires a sophisticated framework for patient monitoring, support, and compliance—a challenge the FDA takes very seriously, as evidenced by its warnings against unapproved compounded ketamine products.

Tasman and Osmind are proactively building this framework. The plan includes a consumer-facing patient app, a longitudinal data registry to track outcomes over time, and a clinician network model to support care. This technology-enabled infrastructure is designed to provide the safety and oversight regulators will demand while empowering patients and their doctors with the tools needed for successful long-term treatment.

"Tasman is developing what we believe will become one of the most important new treatments in psychiatry," commented Jimmy Qian, Co-founder and President of Osmind. "We've spent years building the infrastructure, technology, datasets, and clinical relationships... We look forward to leveraging these assets to support Tasman through Phase 3 today to the technology and care delivery model that will define how patients experience R-107 tomorrow."

With blockbuster sales potential exceeding $2 billion and a strong intellectual property portfolio, R-107 is poised to be a major contender in the rapidly growing TRD market. The strategic alliance with Osmind shows that Tasman Therapeutics, a U.S. affiliate of New Zealand's largest pharmaceutical company, Douglas Pharmaceuticals, is not just developing a pill, but a comprehensive, data-driven ecosystem to ensure its breakthrough therapy can safely and effectively improve the lives of millions.